Filgrastim
Near Add Your Location
Accepting patients
Phase 1 Trial for Patients With Advanced Hematologic Malignancies Undergoing Reduced Intensity Allogeneic HCT With a T-cell Depleted Graft With Infusion of Conventional T-cells and Regulatory T-cells
- Allogeneic Stem Cell Transplant
- Phase 1
Accepting patients
Horse Anti-Thymocyte Globulin (hATG)
Phase II Study of Horse Anti-Thymocyte Globulin (hATG), Cyclosporine, Methylprednisolone, and GCSF (Filgrastim or Pegfilgrastim) in Patients With Aplastic Anemia (AA), or Low/Int-1 Risk Myelodysplastic Syndrome (MDS)
- White Blood Cell Stimulant
- Steroid
- Phase 2
Accepting patients
Gemtuzumab as Part of Chemotherapy
A Phase 2 Study of Fludarabine, Cytarabine, Filgrastim-sndz,Gemtuzumab Ozogamicin and Idarubicin in Newly Diagnosed Core Binding Factor Associated Acute Myelogenous Leukemia
- Antibody Drug Conjugate (ADC)
- Hypomethylating Agents (HMA)
- White Blood Cell Stimulant
- CD33
- Phase 2
Accepting patients
Venetoclax w/ Combination Chemotherapy
A Phase 1b/2 Study of the BCL-2 Inhibitor Venetoclax in Combination With Standard Intensive AML Induction/Consolidation Therapy With FLAG-IDA in Patients With Newly Diagnosed or Relapsed/Refractory AML
- BCL-2 Inhibitor
- Chemotherapy
- Phase 1/2
Accepting patients
MORE
A Pilot Study to Evaluate the Feasibility of Post-Hematopoietic Stem Cell Transplant Prophylaxis With Decitabine Combined With Filgrastim for Children and Young Adults With AML, MDS and Related Myeloid Malignancies
- Hypomethylating Agents (HMA)
- White Blood Cell Stimulant
- Maintenance
- Phase 2
Accepting patients
Decitabine Combination Therapy Pre-ASCT
Sequential Decitabine in Combination With FLAG-Ida Followed Immediately by Reduced-Intensity Conditioning (RIC) Allogeneic Hematopoietic Cell Transplantation (DEC-FLAG-Ida/RIC) for Adults With Myeloid Malignancies at High Risk of Relapse: A Phase 1/2 Study
- Allogeneic Stem Cell Transplant
- Chemotherapy
- Hypomethylating Agents (HMA)
- Phase 1/2
Showing 1-6 of 6